ARQT
Arcutis Biotherapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-22/100
Last price
24.07
▼ 1.08 (4.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
25.04
Prev close
25.15
Day high
25.37
Day low
23.89
Volume
2.57M
Market cap
$3.01B
P/E (TTM)
113.90
52W range
19.30 – 31.77
Day trading desk
Gap from prior close
-0.44%
Prior close 25.15
VWAP
24.06
+0.02% from price
Relative volume
2.01×
Unusually busy
Session range
6.72%
23.89 – 25.49
Position in range
12%
Near session low
ATR (14D)
1.38
5.72% of price
Prior day high
25.39
PDH
Prior day low
24.69
PDL
Bid / ask spread
—
Quote not published
Session volume
4.45M
Avg 2.21M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.58%
-12.5%
1M
+0.08%
-1.1%
3M
-16.07%
-20.6%
6M
+2.79%
-15.4%
YTD
-17.63%
-31.9%
1Y
+20.08%
+3.7%
3Y
+350.47%
+268.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARQT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+3.56K
Net buying
Buy transactions
16
121.19K shares
Sell transactions
20
117.64K shares
Net transactions
+36
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
2.22M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | WELGUS HOWARD G Director |
CONVERSION | 4.10K | $32.48K | Direct |
| Sep 15, 26 | WELGUS HOWARD G Director |
SELL | 4.73K | $114.37K | Direct |
| Sep 8, 26 | MATSUDA MASARU Officer |
SELL | 9.99K | $249.99K | Direct |
| Aug 27, 26 | CURRAN TERRIE Director |
CONVERSION | 38.20K | $317.18K | Direct |
| Aug 27, 26 | CURRAN TERRIE Director |
SELL | 38.20K | $956.12K | Direct |
| Aug 20, 26 | CURRAN TERRIE Director |
CONVERSION | 1.07K | $8.05K | Direct |
| Aug 20, 26 | CURRAN TERRIE Director |
SELL | 1.07K | $27.91K | Direct |
| Aug 19, 26 | BURNETT PATRICK Officer |
SELL | 1.70K | $45.82K | Direct |
| Aug 17, 26 | WELGUS HOWARD G Director |
CONVERSION | 4.10K | $32.48K | Direct |
| Aug 17, 26 | WELGUS HOWARD G Director |
SELL | 4.73K | $123.83K | Direct |
| Aug 12, 26 | BURNETT PATRICK Officer |
CONVERSION | 15.00K | $54.60K | Direct |
| Aug 12, 26 | BURNETT PATRICK Officer |
SELL | 15.00K | $394.90K | Direct |
| Aug 3, 26 | BURNETT PATRICK Officer |
SELL | 955 | $24.94K | Direct |
| Aug 3, 26 | MATSUDA MASARU Officer |
SELL | 1.23K | $32.12K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BURNETT PATRICK |
Officer | 117.59K | Sale |
CHAUDHURI BHASKAR |
Director | 917.81K | Stock Award(Grant) |
EDWARDS LARRY TODD |
Officer | 175.18K | Sale |
HERON PATRICK J |
Director | 8.87M | Stock Award(Grant) |
MATSUDA MASARU |
Officer | 116.18K | Sale |
PEETZ CHRISTOPHER |
Director | 191.81K | Stock Award(Grant) |
TOPPER DAVID JOSEPH |
Chief Financial Officer | 182.77K | Sale |
VAIRAVAN LATHA |
Chief Financial Officer | 85.98K | Sale |
WATANABE TODD FRANKLIN |
Chief Executive Officer | 950.34K | Sale |
WELGUS HOWARD G |
Director | 35.84K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.01B
Enterprise value$2.88B
Revenue (TTM)$463.98M
Gross profit$422.88M
EBITDA$36.50M
Net income$28.52M
EPS (TTM)$0.21
Free cash flow$21.69M
Total cash$238.55M
Total debt$114.14M
Book value / share$1.76
Shares outstanding125.69M
Float93.82M
Short % of float15.66%
Dividend yield0.00%
Beta (5Y)1.58
Valuation & profitability ratios
Trailing P/E113.90
Forward P/E17.59
PEG ratio—
Price / sales—
Price / book13.62
EV / revenue6.21
EV / EBITDA78.96
Gross margin91.14%
Operating margin12.65%
Profit margin6.15%
Return on equity15.86%
Return on assets5.09%
Debt / equity51.74
Current ratio2.92
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $376.07M | $196.54M | $59.61M | $3.69M | +91.3% |
| Operating revenue | $372.07M | $166.54M | $29.19M | $3.69M | +123.4% |
| Cost of revenue | $36.70M | $19.13M | $4.99M | $754.00K | +91.8% |
| Gross profit | $339.38M | $177.41M | $54.62M | $2.93M | +91.3% |
| Research & development | $77.05M | $76.42M | $110.58M | $182.44M | +0.8% |
| Selling, general & admin | $274.55M | $229.39M | $185.15M | $122.12M | +19.7% |
| Total operating expense | $351.60M | $305.81M | $295.72M | $304.56M | +15.0% |
| Operating income | -$12.23M | -$128.40M | -$241.10M | -$301.63M | +90.5% |
| Net interest income | -$3.19M | -$11.04M | -$17.20M | -$15.65M | +71.1% |
| Pre-tax income | -$14.97M | -$139.39M | -$259.03M | -$311.46M | +89.3% |
| Tax provision | $1.17M | $647.00K | $3.11M | $0 | +81.0% |
| Net income | -$16.14M | -$140.04M | -$262.14M | -$311.46M | +88.5% |
| Net income to common | -$16.14M | -$140.04M | -$262.14M | -$311.46M | +88.5% |
| Basic EPS | -0.13 | -1.16 | -3.78 | -5.66 | +88.8% |
| Diluted EPS | -0.13 | -1.16 | -3.78 | -5.66 | +88.8% |
| EBIT | -$2.89M | -$112.22M | -$229.31M | -$295.81M | +97.4% |
| EBITDA | $1.78M | -$110.27M | -$228.56M | -$294.87M | +101.6% |
| Basic shares | 127.23M | 120.96M | 69.31M | 55.03M | +5.2% |
| Diluted shares | 127.23M | 120.96M | 69.31M | 55.03M | +5.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $42.91M | $71.33M | $88.40M | $53.64M | -39.9% |
| Cash & short-term investments | $220.98M | $227.96M | $271.86M | $409.59M | -3.1% |
| Accounts receivable | $146.23M | $73.07M | $25.81M | $8.46M | +100.1% |
| Inventory | $22.63M | $14.53M | $13.13M | $7.51M | +55.8% |
| Total current assets | $411.23M | $335.82M | $330.43M | $437.41M | +22.5% |
| Property, plant & equipment | $5.51M | $2.99M | $3.90M | $4.60M | +84.0% |
| Goodwill & intangibles | $14.81M | $9.48M | $6.44M | $7.19M | +56.3% |
| Total assets | $432.97M | $348.89M | $341.37M | $449.27M | +24.1% |
| Total current liabilities | $129.84M | $81.01M | $46.67M | $37.81M | +60.3% |
| Current debt | $1.00M | — | — | — | — |
| Long-term debt | $107.96M | $107.20M | $201.80M | $197.77M | +0.7% |
| Total debt | $114.22M | $109.77M | $205.92M | $202.54M | +4.1% |
| Total liabilities | $243.49M | $191.35M | $252.70M | $239.69M | +27.3% |
| Retained earnings | -$1.14B | -$1.12B | -$981.90M | -$719.76M | -1.4% |
| Shareholder equity | $189.48M | $157.54M | $88.67M | $209.58M | +20.3% |
| Working capital | $281.39M | $254.81M | $283.76M | $399.60M | +10.4% |
| Net tangible assets | $174.67M | $148.06M | $82.23M | $202.39M | +18.0% |
| Shares issued | 123.33M | 117.85M | 96.79M | 61.04M | +4.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$16.14M | -$140.04M | -$262.14M | -$311.46M | +88.5% |
| Depreciation & amortisation | $4.67M | $1.96M | $750.00K | $934.00K | +138.2% |
| Stock-based compensation | $40.36M | $41.73M | $38.81M | $32.68M | -3.3% |
| Change in working capital | -$34.83M | -$15.08M | -$23.50M | -$10.18M | -131.0% |
| Operating cash flow | -$5.63M | -$112.16M | -$247.06M | -$257.71M | +95.0% |
| Capital expenditure | -$10.69M | -$5.14M | -$428.00K | -$23.28M | -107.8% |
| Investing cash flow | -$30.25M | $28.82M | $180.23M | -$87.20M | -205.0% |
| Financing cash flow | $6.97M | $66.20M | $101.32M | $301.80M | -89.5% |
| Free cash flow | -$16.31M | -$117.30M | -$247.49M | -$281.00M | +86.1% |
| End cash position | $43.22M | $71.95M | $89.32M | $54.88M | -39.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $129.86M | $105.40M | $129.50M | $99.22M | $81.50M | +23.2% |
| Operating revenue | $129.86M | $105.40M | $127.50M | $99.22M | $81.50M | +23.2% |
| Cost of revenue | $10.94M | $9.78M | $11.69M | $8.69M | $7.49M | +11.8% |
| Gross profit | $118.92M | $95.61M | $117.81M | $90.53M | $74.01M | +24.4% |
| Research & development | $20.36M | $30.63M | $20.45M | $19.60M | $19.45M | -33.5% |
| Selling, general & admin | $82.14M | $74.08M | $78.98M | $62.40M | $69.17M | +10.9% |
| Total operating expense | $102.49M | $104.70M | $99.43M | $82.01M | $88.62M | -2.1% |
| Operating income | $16.43M | -$9.09M | $18.39M | $8.53M | -$14.61M | +280.8% |
| Net interest income | -$1.13M | -$2.09M | $5.90M | -$3.07M | -$953.00K | +46.2% |
| Pre-tax income | $15.14M | -$11.20M | $17.86M | $7.49M | -$15.54M | +235.2% |
| Tax provision | $136.00K | $93.00K | $470.00K | $80.00K | $342.00K | +46.2% |
| Net income | $15.01M | -$11.29M | $17.39M | $7.41M | -$15.89M | +232.9% |
| Net income to common | $15.01M | -$11.29M | $17.39M | $7.41M | -$15.89M | +232.9% |
| Basic EPS | 0.11 | -0.09 | 0.14 | 0.06 | -0.13 | +222.2% |
| Diluted EPS | 0.11 | -0.09 | 0.13 | 0.06 | -0.13 | +222.2% |
| EBIT | $18.55M | -$6.83M | $20.87M | $10.56M | -$12.52M | +371.5% |
| EBITDA | $19.11M | -$6.27M | $21.43M | $11.12M | -$11.95M | +404.8% |
| Basic shares | 130.52M | 129.37M | 128.25M | 127.62M | 127.00M | +0.9% |
| Diluted shares | 135.90M | 129.37M | 135.63M | 132.88M | 127.00M | +5.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.12M | $34.76M | $42.91M | $47.12M | $72.74M | -1.8% |
| Cash & short-term investments | $238.55M | $224.00M | $220.98M | $191.07M | $190.82M | +6.5% |
| Accounts receivable | $155.16M | $144.38M | $146.23M | $115.12M | $106.69M | +7.5% |
| Inventory | $38.88M | $37.39M | $22.63M | $22.42M | $16.32M | +4.0% |
| Total current assets | $467.67M | $438.06M | $411.23M | $349.22M | $332.78M | +6.8% |
| Property, plant & equipment | $5.13M | $5.40M | $5.51M | $5.78M | $3.12M | -5.1% |
| Goodwill & intangibles | $13.69M | $14.25M | $14.81M | $15.38M | $15.94M | -4.0% |
| Total assets | $488.54M | $460.00M | $432.97M | $370.98M | $352.43M | +6.2% |
| Total current liabilities | $160.34M | $163.20M | $129.84M | $99.77M | $103.94M | -1.8% |
| Current debt | $6.95M | $7.95M | $1.00M | $1.00M | $1.00M | -12.6% |
| Long-term debt | $101.95M | $101.47M | $107.96M | $107.50M | $107.05M | +0.5% |
| Total debt | $114.14M | $114.67M | $114.22M | $113.77M | $110.16M | -0.5% |
| Total liabilities | $267.96M | $270.36M | $243.49M | $212.90M | $213.46M | -0.9% |
| Retained earnings | -$1.13B | -$1.15B | -$1.14B | -$1.16B | -$1.16B | +1.3% |
| Shareholder equity | $220.58M | $189.65M | $189.48M | $158.07M | $138.97M | +16.3% |
| Working capital | $307.33M | $274.85M | $281.39M | $249.45M | $228.84M | +11.8% |
| Net tangible assets | $206.89M | $175.40M | $174.67M | $142.70M | $123.04M | +18.0% |
| Shares issued | 125.59M | 125.04M | 123.33M | 120.29M | 119.80M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $15.01M | -$11.29M | $17.39M | $7.41M | -$15.89M | — | +232.9% |
| Depreciation & amortisation | $563.00K | $562.00K | $563.00K | $562.00K | $563.00K | — | +0.2% |
| Stock-based compensation | $12.76M | $10.69M | $10.06M | $10.04M | $10.49M | — | +19.4% |
| Change in working capital | -$16.23M | $1.79M | -$2.33M | -$19.94M | $5.13M | — | -1,007.2% |
| Operating cash flow | $12.64M | $2.24M | $26.18M | -$1.75M | $324.00K | — | +464.5% |
| Capital expenditure | — | — | — | — | -$10.08M | -$608.00K | — |
| Investing cash flow | -$15.22M | -$11.33M | -$34.18M | -$25.25M | $17.42M | — | -34.3% |
| Financing cash flow | $1.99M | $1.07M | $3.72M | $1.48M | $1.38M | — | +86.5% |
| Free cash flow | $12.48M | $2.24M | $26.18M | -$1.75M | -$9.75M | — | +457.4% |
| End cash position | $34.43M | $35.07M | $43.22M | $47.43M | $73.05M | — | -1.8% |
Options analytics
Put / call volume
1.08
Put-heavy session
Put / call open interest
0.06
Positioning, not flow
Max pain
27.50
+15.0% from spot
ATM implied vol
88.3%
Nearest strike to spot
Skew (10% OTM)
+55.1%
Puts bid over calls
Call volume
50
Contracts, this expiry
Put volume
54
Contracts, this expiry
Heaviest call OI
27.50
4.36K contracts
Heaviest put OI
27.50
233 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.05 | 0.11 | +120.0% |
| Mar 2026 | -0.06 | -0.09 | -55.2% |
| Dec 2025 | 0.09 | 0.13 | +46.8% |
| Sep 2025 | -0.09 | 0.06 | +163.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.17 | 5 | $141.69M | +42.8% |
| Next quarter | 0.23 | 5 | $160.15M | +23.7% |
| Current year | 0.43 | 5 | $537.34M | +42.9% |
| Next year | 1.36 | 5 | $686.92M | +27.8% |
Analyst targets & ownership
Mean target$37.00
High target$40.00
Low target$34.00
Implied upside53.72%
Analyst count7
ConsensusNONE
Strong buy / Buy2 / 4
Hold1
Sell / Strong sell0 / 0
Held by insiders1.77%
Held by institutions108.73%
Institutions holding387
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.96
-7.28% from price
SMA 20
25.51
-6.23% from price
SMA 50
25.57
-6.46% from price
SMA 100
25.17
-4.37% from price
SMA 200
25.17
-4.96% from price
EMA 12
25.53
-5.71% from price
EMA 26
25.52
-5.69% from price
EMA 50
25.51
-5.63% from price
RSI (14)
40.5
Neutral
MACD (12,26,9)
0.01
Hist -0.19
ATR (14)
1.38
5.76% of price
Realised vol 30D
52.2%
Annualised
Bollinger upper
28.12
20, 2σ
Bollinger lower
22.90
20, 2σ
50 / 200 cross
Golden
25.57 vs 25.17
Trend bias
Below 200
-4.96%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.06
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
52.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-37.5%
Peak to trough
Max drawdown 5Y
-93.2%
Peak to trough
ATR 14
1.38
5.76% of price
Beta (reported)
1.58
5Y monthly, from filing
Short interest
Shares short
18.46M
Prior 14.72M
Change vs prior
+25.4%
Shorts adding
% of float
15.66%
Elevated
% of shares out
14.69%
Against total outstanding
Days to cover
9.3
Crowded exit
Float
93.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Needham | MAINTAINED | Buy | Buy |
| May 7, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 2, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Feb 27, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Feb 26, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Feb 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 26, 26 | Needham | MAINTAINED | Buy | Buy |
| Jan 26, 26 | Needham | MAINTAINED | Buy | Buy |
| Nov 28, 25 | Mizuho | MAINTAINED | Outperform | Outperform |
| Oct 30, 25 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-16
Corporate Changes & Voting Matters
8-K · 2026-06-09
Periodic Financial Reports
10-Q · 2026-05-06
Proxy Statements
DEF 14A · 2026-04-21
Offering Registrations
S-8 · 2026-02-25
Corporate Changes & Voting Matters
8-K · 2025-12-08
Periodic Financial Reports
10-Q · 2025-10-28
Headlines
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
GlobeNewswire · 16h ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 4d ago
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
Zacks · 6d ago
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
GlobeNewswire · 8d ago
AXT Inc. (AXTI) Climbs 16% on S&P 600 Addition
Insider Monkey · 15d ago
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Zacks · 16d ago
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
Zacks · 20d ago
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Zacks · 20d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.